You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
口罩、疫苗、检测等板块集体走强!疫情反弹下抗疫题材“卷土重来”
格隆汇 06-17 11:28

源于北京新发地疫情爆发的影响,今日口罩、疫苗等相关概念股涨嗨了。

截至发稿,口罩板块中,鹿港文化冲击涨停,南卫股份涨超8%,海王生物涨超6%,雷赛智能、奥美医疗、泰达股份、英科医疗均涨超4%,尚荣医疗、道恩股份等概念股皆大幅跟涨。

(行情来源:同花顺)

而疫苗概念股亦有所活跃。截至发稿,神奇制药、现代制药迅速涨停,华兰生物、达安基因、海王生物皆涨超6%,鲁抗医药、海正医药、未名医药等股则随之走强。

(行情来源:同花顺)

除此之外,新冠肺炎检测板块也集体走强。截止发稿,安科生物涨超8%,达安基因涨超7%,热景生物涨超6%,硕世生物、华大基因、迈克生物等股纷纷跟涨。

(行情来源:同花顺)

结合当下新冠疫情的具体情况来看,此轮抗疫题材走强主要是受北京疫情加剧之下,应急响应级别由三级提升到二级这一相关消息刺激的。

6月13日,北京新增报告本地确诊病例36例,累计报告本地确诊病例463例;6月14日,北京新增报告本地确诊病例36例,累计报告本地确诊病例499例;6月15日,北京新增报告本地确诊病例27例,累计报告本地确诊病例526例;而截至6月16日,北京新增报告本地确诊病例31例,累计报告本地确诊病例557例。

北京本土四日新增130例,这一数据无不向外界传达了一个信号——北京受疫情的影响程度,恐怕要比外界想象中的更加严峻。

在此背景之下,北京应急响应级别连夜由三级提升到二级。6月16日晚,北京市政府副秘书长陈蓓在会上通报,近日在国家卫生健康委专家组的指导下进行分析,经北京市新冠肺炎防控工作领导小组研究决定,自6月16日即时起北京市应急响应级别由三级调至二级。

其中,在核酸检测方面,北京强力扩大核酸检测范围。据北京市政府副秘书长陈蓓,境外入京人员全部集中观察核酸检测,中高风险街乡、新发地市场相关人员禁止出京。其他人员坚持非必要不出京,确需离京的,要持7日内核酸检测阴性证明。在十类人员核酸检测应检尽检的基础上,对过去14天内到过新发地、玉泉东、天陶红莲市场等重点区域人员及密接者落实检测全覆盖,并根据需要扩大检测范围。

在口罩等防护用品的佩戴上,北京市政府副秘书长陈蓓表示,农贸市场、菜市场、餐饮店、单位食堂等场所相关从业人员必须佩戴口罩和手套。医疗卫生等专业机构、从事公共服务人员等必须佩戴口罩。小于1米近距离接触、处于人员密集、封闭拥挤场所,必须佩戴口罩。此外,北京市教委发布7条校园“新规”表示:学生上课全程必须佩戴戴口罩。

值得注意的是,上述防疫措施的升级也使得口罩、消毒液等防疫物品销量大幅飙升。

6月14日,阿里健康大药房口罩购买量环比增加5倍。同日百度搜索大数据显示,口罩再次成为大家关注的重点,“医用口罩品牌”搜索热度也在近24个小时内飙升20倍。此外,拼多多数据显示,6月12日至14日三天平台口罩和消毒液的销量同比上月销售增长200%,环比上周增长400%;而苏宁易购数据显示,6月13日-14日,苏宁超市口罩销量暴增300.5%。

对此,长城证券表示,短期来看,疫情的反复有望持续加深市场投资者对医药板块的青睐,建议重点关注检测、疫苗、防护等细分领域;长期来看,政策不断推动重大疫情防控体系建设,疫情的反复或将加快财政投入力度,利好医药行业的长期稳健发展。

此外,新时代证券也表示,疫情有所反复,建议关注受益的口罩机、注塑机产业:国内外疫情反复背景下,预计有所放松的防疫要求将再次提高,如口罩佩戴、核酸检测、温度测量等,对应的防疫用品需求将再次提高,包括口罩、额温枪等。另外国内外疫情反复,居民对食品及生活用品进行囤货,冰箱冰柜等家电需求持续旺盛。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account